AdjuCor’s first international conference presentation has been confirmed – 41st ISHLT Annual Meeting & Scientific Sessions

For the very first time, AdjuCor GmbH`s revolutionary new heart-assist technology – BEAT – will take the stage at the prestigious 41st International Society for Heart and Lung Transplantation (#ISHLT2021). Prof. Ulrich Stock will be presenting BEAT’s acute and chronic preclinical results, proudly showcasing this first-in-class technology and how it can assist the failing heart.

Professor Ulrich Stock, Consultant Cardiothoracic Surgeon and Heart Failure specialist at Royal Brompton and Harefield Hospitals in London, UK, will present the most recent results from a very fruitful collaboration of pre-clinical experiments.

“As far as we can determine, there has never before been any active, extra-cardiac device for mechanical circulatory support that has demonstrated 30- and 60-day pre-clinical survival. Until now”, as commented by AdjuCor’s CEO, Professor Stephen Wildhirt. He further added, “The timing for disclosing the remarkable progress that we have been making is ideal – the ISHLT meeting is exactly the right platform for doing this.”

Due to the continued COVID-19 pandemic, the organizers of the 41st ISHLT Annual Meeting & Scientific Sessions have decided upon hosting a virtual event. More details, including finalization of the meeting program will be announced shortly.

AdjuCor’s Innovative Extravascular, Biventricular Cardiac Support Technology

What sets AdjuCor’ patented technology apart from the other LVADs currently available on the market, is its unique non-blood-contacting solution, its ability to support both ventricles, and its innovative patientspecific design. It is implanted by a heart team (cardiologist and surgeon) around the heart within a few minutes on the beating heart without sutures. It completely avoids blood contact and thereby any bloodrelated complications including strokes and bleeding – an invaluable advantage that cannot be over-stated.

The energy transferred to the heart may be adjusted to each patient’s need. It thereby dramatically enhances the care of patients with heart failure and improves their quality of life. AdjuCor was founded as GmbH in 2012 by the Cardiothoracic Surgeon Stephen Wildhirt and is funded by private investors, the European Union, as well as German and Bavarian entities. The company employs over thirty experts in all fields required and has received over 13 million euros of financing.